Australia-based drug development company Kazia Therapeutics Limited (NASDAQ: KZIA) announced on Monday that it has been granted a Type C meeting with the U.S. FDA in December 2024 to discuss potential registration pathways for paxalisib, its PI3K/mTOR inhibitor for treating newly diagnosed glioblastoma multiforme (GBM).
Kazia's paxalisib, which crosses the blood-brain barrier, showed promising results in a Phase II/III trial (GBM-AGILE), with improved overall survival for unmethylated GBM patients.
The company's corporate presentation now includes preliminary trial data from GBM-AGILE, accessible on Kazia's website. Kazia will also participate in the Society for Neuro-Oncology Annual Meeting and the San Antonio Breast Cancer Symposium later this year, offering opportunities to engage with investors and stakeholders.
Paxalisib holds Orphan Drug and Fast Track Designations from the FDA for glioblastoma and other rare CNS cancers. Kazia is also advancing EVT801, a VEGFR3 inhibitor, in clinical trials following successful preclinical outcomes, with data presented at the Ovarian Cancer Research Symposium in September 2024.
FDA grants priority review to Innoviva's zoliflodacin for treatment of gonorrhea
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
US FDA approves expanded indication for AbbVie's MAVYRET (glecaprevir/pibrentasvir) in acute HCV
Creo Medical secures FDA clearance for SpydrBlade Flex in US market
Psilera collaborates with Hesperos for PSIL-006 preclinical modelling for frontotemporal dementia
Myosin Therapeutics' MT-125 cleared by US FDA to initiate first-in-human trial in glioblastoma
Ondine's Steriwave proven effective against deadly Mucor fungus
AB Science receives EMA approval to extend Masivet shelf life to four years
Hemispherian's GLIX1 receives positive EU opinion for orphan designation in glioma
Arvinas and Pfizer submit FDA application for vepdegestrant in ESR1-mutated breast cancer
NRx Pharmaceuticals files ANDA for preservative-free IV ketamine
Innovent's IBI363 granted second breakthrough therapy designation in China
Implantica reports positive NICE guidance for RefluxStop procedure in UK hospitals